EU/3/14/1390: Orphan designation for the treatment of hereditary haemorrhagic telangiectasia



On 16 December 2014, orphan designation (EU/3/14/1390) was granted by the European Commission to Sophie Dupuis-Girod, France, for bevacizumab for the treatment of hereditary haemorrhagic telangiectasia.

Key facts

Active substance
Intended use
Treatment of hereditary haemorrhagic telangiectasia
Orphan designation status
EU designation number
Date of designation

Laboratoires Delbert
49 Rue Rouelle
75015 Paris

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Update history

December 2022The sponsorship was transferred from Dr Sophie Dupuis-Girod, France to Laboratoires Delbert, France.

Documents related to this orphan designation evaluation

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

How useful was this page?

Add your rating